Company Overview - Bandwidth (BAND) shares have increased by approximately 2.7% over the past month, underperforming the S&P 500 index [1] - The most recent earnings report is crucial for understanding the catalysts affecting the stock [1] Earnings Estimates - Estimates for Bandwidth have remained flat over the past month, with a significant shift of 300% in the consensus estimate [2] VGM Scores - Bandwidth has a strong Growth Score of A, but a low Momentum Score of F, and a Value Score of B, placing it in the second quintile for investment strategy [3] - The aggregate VGM Score for Bandwidth is A, indicating a strong overall performance across different investment strategies [3] Market Outlook - Bandwidth holds a Zacks Rank of 3 (Hold), suggesting an expectation of in-line returns in the upcoming months [4] Industry Performance - Bandwidth is part of the Zacks Communication - Infrastructure industry, where another player, CommScope (COMM), has seen a 19.5% increase in shares over the past month [5] - CommScope reported revenues of $1.11 billion for the last quarter, reflecting a year-over-year decline of 4.8%, with an EPS of $0.14 compared to -$0.08 a year ago [5] - CommScope is projected to have earnings of $0.24 per share for the current quarter, indicating a year-over-year decrease of 29.4% [6] - The Zacks Consensus Estimate for CommScope has remained unchanged over the last 30 days, and it also holds a Zacks Rank of 3 (Hold) [6]

Company Overview - CRISPR Therapeutics AG (CRSP) shares have increased by approximately 11.1% over the past month, outperforming the S&P 500 [1] - The most recent earnings report is essential for understanding the key drivers behind this performance [1] Earnings Estimates - Estimates for CRISPR Therapeutics have trended downward over the past month, with a consensus estimate shift of -20.48% [2] - The stock currently holds a Zacks Rank 3 (Hold), indicating an expectation of in-line returns in the coming months [4] VGM Scores - CRISPR Therapeutics has an average Growth Score of C and a Momentum Score of B, but a low Value Score of F, placing it in the bottom 20% for this investment strategy [3] - The overall aggregate VGM Score for the stock is D, which is relevant for investors not focused on a single strategy [3] Industry Performance - CRISPR Therapeutics is part of the Zacks Medical - Biomedical and Genetics industry, where Exact Sciences (EXAS) has gained 3.6% over the past month [5] - Exact Sciences reported revenues of $706.78 million for the last quarter, reflecting a year-over-year increase of +10.9% [5] - The expected loss for Exact Sciences in the current quarter is $0.08 per share, with a year-over-year change of +11.1% [6]

Core Viewpoint - Krystal Biotech, Inc. has experienced a decline of approximately 3.5% in share price over the past month, underperforming the S&P 500, raising questions about its upcoming earnings release and potential breakout [1] Estimates Movement - Estimates for Krystal Biotech have trended downward over the past month, with a consensus estimate shift of -12.86% [2] VGM Scores - Krystal Biotech holds a Growth Score of A, but has a low Momentum Score of F. The stock has a value grade of C, placing it in the middle 20% for this investment strategy, resulting in an aggregate VGM Score of C [3] Outlook - The overall trend of downward estimate revisions suggests a negative outlook for Krystal Biotech, which currently holds a Zacks Rank of 3 (Hold), indicating an expectation of in-line returns in the coming months [4] Industry Performance - Krystal Biotech is part of the Zacks Medical - Biomedical and Genetics industry. In contrast, Biogen Inc., another player in the same industry, has seen a gain of 12.5% over the past month [5] Biogen's Financials - Biogen reported revenues of $2.43 billion for the last quarter, reflecting a year-over-year increase of +6.1%. The EPS for the same period was $3.02, down from $3.67 a year ago [5] Biogen's Future Estimates - For the current quarter, Biogen is expected to report earnings of $4.11 per share, indicating a decline of -22.2% from the previous year. The Zacks Consensus Estimate for Biogen has changed by -0.6% over the last 30 days, and it also holds a Zacks Rank of 3 (Hold) [6]

Group 1 - Myriad Genetics (MYGN) shares have increased by approximately 23.9% over the past month, outperforming the S&P 500 [1] - Recent estimates for Myriad have trended downward, with a consensus estimate shift of -5.56% [2] - Myriad has a Growth Score of A, a Momentum Score of F, and a Value Score of C, resulting in an aggregate VGM Score of C [3] Group 2 - The overall outlook for Myriad indicates a downward shift in estimates, with a Zacks Rank of 3 (Hold), suggesting an in-line return expected in the coming months [4] - Myriad is part of the Zacks Medical - Biomedical and Genetics industry, where GSK has gained 9.8% over the past month [5] - GSK reported revenues of $9.46 billion for the last quarter, reflecting a year-over-year increase of +1.4% [5]

Company Overview - Recursion Pharmaceuticals (RXRX) shares have increased by approximately 5.7% over the past month, underperforming the S&P 500 [1] - The most recent earnings report is crucial for understanding the stock's performance and potential catalysts [1] Earnings Estimates - Estimates for Recursion Pharmaceuticals have trended upward in the past month, with a consensus estimate shift of 10.13% [2] VGM Scores - The company has a poor Growth Score of F, a Momentum Score of A, and a Value Score of F, placing it in the bottom 20% for the value investment strategy [3] - The aggregate VGM Score for Recursion Pharmaceuticals is F, indicating a lack of focus on any single investment strategy [3] Outlook - The upward trend in estimates is promising, and Recursion Pharmaceuticals holds a Zacks Rank of 3 (Hold), suggesting an expectation of in-line returns in the coming months [4] Industry Comparison - Recursion Pharmaceuticals is part of the Zacks Medical - Drugs industry, where Ionis Pharmaceuticals (IONS) has gained 9.1% over the past month [5] - Ionis Pharmaceuticals reported revenues of $132 million for the last quarter, reflecting a year-over-year increase of 10.9% [5] - For the current quarter, Ionis Pharmaceuticals is expected to report a loss of $0.14 per share, indicating a 68.9% improvement from the previous year [6]

Core Viewpoint - eBay shares have increased by approximately 7.5% since the last earnings report, outperforming the S&P 500, raising questions about the sustainability of this positive trend leading up to the next earnings release [1] Group 1: Earnings Report Insights - Recent earnings report indicates that estimates for eBay have trended upward over the past month, suggesting positive momentum [2] - The stock has a strong Growth Score of A, but a lower Momentum Score of C, and a Value Score of C, placing it in the middle 20% for the value investment strategy [3] Group 2: Future Outlook - The upward trend in estimates is promising, and eBay holds a Zacks Rank of 3 (Hold), indicating expectations for an in-line return in the coming months [4]

Company Overview - Tandem Diabetes Care, Inc. (TNDM) has seen its shares increase by approximately 6.5% over the past month, outperforming the S&P 500 [1] - The most recent earnings report is crucial for understanding the key drivers affecting the stock [1] Earnings Estimates - Estimates for Tandem Diabetes Care have trended downward over the past month, with the consensus estimate shifting by -19.45% [2] - The stock currently holds a Zacks Rank of 3 (Hold), indicating expectations for an in-line return in the coming months [4] VGM Scores - Tandem Diabetes Care has an average Growth Score of C, a Momentum Score of F, and a Value Score of C, placing it in the middle 20% for the value investment strategy [3] - The overall aggregate VGM Score for the stock is D, which is significant for investors not focused on a single strategy [3] Industry Performance - Tandem Diabetes Care is part of the Zacks Medical - Instruments industry, where another player, Intuitive Surgical, Inc. (ISRG), has gained 7.5% in the past month [5] - Intuitive Surgical reported revenues of $2.25 billion for the last quarter, reflecting a year-over-year increase of +19.2% [5] - The expected earnings for Intuitive Surgical in the current quarter are $1.92 per share, indicating a +7.9% change from the previous year [6]

A month has gone by since the last earnings report for Paypal (PYPL) . Shares have added about 8.5% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Paypal due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.How Have Estimates Been Moving Since Then?It turns out, fresh es ...

Core Viewpoint - Universal Health Services (UHS) shares have increased by approximately 12% over the past month, outperforming the S&P 500, raising questions about the sustainability of this trend leading up to the next earnings release [1] Estimates Movement - Estimates for Universal Health Services have trended upward over the past month, indicating positive sentiment among analysts [2] VGM Scores - Universal Health Services currently holds a strong Growth Score of A, a Momentum Score of B, and a Value Score of A, placing it in the top 20% for the value investment strategy, resulting in an aggregate VGM Score of A [3] Outlook - The upward trend in estimates suggests a promising outlook for Universal Health Services, which currently has a Zacks Rank of 3 (Hold), indicating expectations for an in-line return in the coming months [4] Industry Performance - Universal Health Services is part of the Zacks Medical - Hospital industry, where HCA Healthcare has gained 11.2% over the past month, reporting revenues of $18.32 billion for the last quarter, reflecting a year-over-year increase of 5.7% [5] - HCA is projected to report earnings of $6.20 per share for the current quarter, representing a year-over-year change of 12.7%, with the Zacks Consensus Estimate remaining unchanged over the last 30 days, also holding a Zacks Rank of 3 (Hold) and a VGM Score of A [6]

Core Viewpoint - Boston Scientific shares have increased by approximately 3.3% over the past month, underperforming the S&P 500 index [1] Group 1: Earnings and Estimates - Estimates for Boston Scientific have trended upward in the past month, indicating positive sentiment among analysts [2] - The most recent earnings report highlighted important drivers for the stock's performance [1] Group 2: VGM Scores - Boston Scientific has a Growth Score of B, a Momentum Score of C, and a Value Score of D, placing it in the bottom 40% for the value investment strategy [3] - The aggregate VGM Score for Boston Scientific is C, which is relevant for investors not focused on a single strategy [3] Group 3: Outlook - The upward trend in estimates suggests a promising outlook for Boston Scientific, with a Zacks Rank of 3 (Hold), indicating an expectation of in-line returns in the coming months [4] Group 4: Industry Performance - Boston Scientific is part of the Zacks Medical - Products industry, where Abbott has gained 1.6% over the past month [5] - Abbott reported revenues of $10.36 billion for the last quarter, reflecting a year-over-year increase of 4%, with EPS rising from $0.98 to $1.09 [5] - For the current quarter, Abbott is expected to post earnings of $1.25 per share, representing a 9.7% increase from the previous year [6]